ABSTRACT
Intravenous immunoglobulin (IVIG) has had a major impact on the treatment of neurological disorders in the years since 1990. It was around that time that I became interested in IVIG but discovered that the industry had no interest in supporting clinical trials with IVIG in the field of neurology in the USA, despite the fact that a few reports had already been published from Europe on the treatment of myasthenia gravis1,2, Guillain-Barré syndrome3 and chronic inflammatory polyneuropathy4. Although IVIG was unknown to the neurology field in the USA and, in spite of difficulties, we managed to launch the first controlled clinical trials at the National Institutes of Health (NIH) in 1990. Our first report on dermatomyositis was published in 19935.
